Clinical Trial Update: Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating NalirIFOX (nal-IRI plus 5-FU/leucovorin) for advanced unresectable small bowel tumors, specifically small bowel adenocarcino…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Bowel Adenocarcinoma

Drugs mentioned

• NALIRIFOX (liposomal irinotecan + 5-fluorouracil/leucovorin)

Snippet

Sponsor: Tiago Biachi de Castria | Conditions: Small Bowel Adenocarcinoma | Phase 2 | Status: RECRUITING